Modulating Treg cell activity in prostate cancer via chitosan nanoparticles loaded with si-BATF/PRDM1

ZhanPeng Zhao; RunZe An; WenMin Tang; JiaHua Chen; Rui Xu; Liang Kan

doi:10.1016/j.intimp.2024.113445

Modulating Treg cell activity in prostate cancer via chitosan nanoparticles loaded with si-BATF/PRDM1

Int Immunopharmacol. 2024 Nov 21:144:113445. doi: 10.1016/j.intimp.2024.113445. Online ahead of print.

Authors

ZhanPeng Zhao¹, RunZe An¹, WenMin Tang¹, JiaHua Chen², Rui Xu¹, Liang Kan³

Affiliations

¹ Department of Family Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, China.
² Department of Geriatrics, Shengjing Hospital of China Medical University, Shenyang 110004, China.
³ Department of Geriatrics, Shengjing Hospital of China Medical University, Shenyang 110004, China. Electronic address: 20051150@cmu.edu.cn.

PMID: 39577215
DOI: 10.1016/j.intimp.2024.113445

Abstract

Prostate cancer is a significant health issue, with regulatory T (Treg) cells playing a crucial role in its progression. This study explores the potential of chitosan-modified magnetic nanoparticles loaded with si-BATF/PRDM1 to target Treg cell activity in impeding prostate cancer development. By understanding the function of BATF and PRDM1 in Treg cells, the research demonstrates their central involvement in prostate cancer progression. Through experiments in vitro and in vivo, including single-cell sequencing and gene silencing assays, chitosan nanoparticles efficiently deliver siRNA, inhibiting BATF and PRDM1 expression. This inhibition leads to suppressed tumor growth and metastasis in prostate cancer models. The findings highlight the promise of nanoparticle-based approaches in modulating Treg cell activity for prostate cancer therapy, offering a potential avenue for precision medicine interventions in combating this prevalent malignancy.

Keywords: BATF; Chitosan; Nanoparticles; PRDM1; Prostate cancer; Treg cells.